Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2018 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study.
Doosti R, Naser Moghadasi A, Azimi AR, Karbalai Saleh S, Etemadifar M, Shaygannejad V, Ashtari F, Harirchian MH, Siroos SB, Ayramloo H, Majdinasab N, Hojjati SMM, Asghari N, Baghbanian SM, Cheraghmakani H, Abedini M, Sedighi B, Mohseni Abbas Abadi N, Ghasemitabar M, Talebianpour S, Babayi Daylari T, Dana V, Ghaleh Noie N, Sahraian MA. Doosti R, et al. Among authors: asghari n. Caspian J Intern Med. 2021 Apr;12(3):263-274. doi: 10.22088/cjim.12.3.263. Caspian J Intern Med. 2021. PMID: 34221275 Free PMC article.
Neutralizing antibody production against Rebif® and ReciGen® in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability.
Shokrollahi Barough M, Ashtari F, Sadat Akhavi M, Asghari N, Mosayebi G, Mirmohammadkhani M, Kokhaei N, Bahraminia F, Ajami A, Kokhaei P. Shokrollahi Barough M, et al. Among authors: asghari n. Int Immunopharmacol. 2018 Sep;62:109-113. doi: 10.1016/j.intimp.2018.06.032. Epub 2018 Jul 7. Int Immunopharmacol. 2018. PMID: 29990690 Clinical Trial.